RE Reuters Zymeworks strikes $929 million deal for Theravance Biopharma
Reuters
- Sources
- Reuters
- Markets
- Stocks
- Active symbols
- NASDAQ:TBPH, NASDAQ:ZYME
- Language
- English
Drugmaker Zymeworks NASDAQ:ZYME said on Monday it will buy Theravance Biopharma NASDAQ:TBPH in a $929 million deal.
